VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

T. annulata Tams1 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. annulata Tams1 Protein Vaccine
  • Target Pathogen: Theileria annulata
  • Target Disease: Theileriosis
  • Vaccine Ontology ID: VO_0004181
  • Type: Subunit vaccine
  • Status: Research
  • TA17050 merozoite-piroplasm surface antigen Tams1 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000757
    • Description: Immunostimulating complexes (ISCOMs) (d'Oliveira et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cattle Response

  • Vaccination Protocol: Calves were immunized via intramuscular injection with 1 ml ISCOM vaccine given intramuscularly, containing 20 μg re-(Tamsl-l or Tams1 -2) (d'Oliveira et al., 1997).
  • Challenge Protocol: Calves were challenged with T. annulata Ankara strain (d'Oliveira et al., 1997).
  • Efficacy: All calves vaccinated with ISCOMs proved to be protected from T. annulata infection and had generated antibodies against both re-(Tams1-1 and Tams1-2) at the time of challenge (d'Oliveira et al., 1997).
References
d'Oliveira et al., 1997: d'Oliveira C, Feenstra A, Vos H, Osterhaus AD, Shiels BR, Cornelissen AW, Jongejan F. Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems. Vaccine. 1997; 15(16); 1796-1804. [PubMed: 9364686].